市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Akebia Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 价值 35% | -0.8 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -0.8 |
| 时机 35% | -2.5 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -2.5 |
| 技术平均移动指标 参考 | -2.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.16 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -6.1% |
| 支柱一致性 | ×1.25 |
| 不计入评分 | |
| 价格波动 参考 | 3.0 |
| 最终评分 | -1.68 |
|
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Core |
| 内部持股比例 | 3.59% |
| 机构持股比例 | 38.96% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Aqr Capital Management Llc | 30 Jun 2026 | 9,151,524 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 4,273,026 |
| Millennium Management Llc | 30 Jun 2026 | 3,196,605 |
| Charles Schwab Investment Management Inc | 30 Jun 2026 | 2,300,438 |
| Northern Trust Corp | 30 Jun 2026 | 2,160,365 |
该时间范围内无数据。
投资组合